Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczyńska A, Banerjee R, Pianko MJ, Martínez-López J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM, MonumenTAL-3 Investigators.

Open source

DOI
10.1056/nejmoa2604657
Published
2026-06-13
Container
N Engl J Med
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2604657,
  title = {Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.},
  author = {Mina R and  Beksac M and  Rodríguez-Otero P and  Chen W and  Mateos MV and  Li J and  Moreau P and  Cohen YC and  Min CK and  Jelinek T and  Ye JC and  Magen H and  Rubinstein SM and  Fu W and  Hungria V and  Cengiz Seval G and  Farias JS and  Radocha J and  Maral S and  Turgut M and  Koh Y and  O'Leary D and  Schmidt Filho J and  Thertulien R and  An G and  Huang SY and  Grosicki S and  Tyczyńska A and  Banerjee R and  Pianko MJ and  Martínez-López J and  Steckiewicz P and  Maruyama D and  Fukushima K and  Oriol A and  Lopez Pardo J and  Goldschmidt H and  Pawlyn C and  Perrot A and  Zamagni E and  Dimopoulos MA and  Rasche L and  Tolbert J and  Terry W and  Courtoux C and  Liu X and  Vasey SY and  Connors K and  Festa M and  Heuck C and  Langlois A and  O'Rourke L and  Zhou J and  Qin X and  Lu J and  Gong J and  Vieyra D and  Voorhees PM and  MonumenTAL-3 Investigators.},
  year = {2026},
  journal = {N Engl J Med},
  doi = {10.1056/nejmoa2604657},
  url = {https://doi.org/10.1056/nejmoa2604657}
}

RIS

TY  - JOUR
TI  - Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
AU  - Mina R
AU  -  Beksac M
AU  -  Rodríguez-Otero P
AU  -  Chen W
AU  -  Mateos MV
AU  -  Li J
AU  -  Moreau P
AU  -  Cohen YC
AU  -  Min CK
AU  -  Jelinek T
AU  -  Ye JC
AU  -  Magen H
AU  -  Rubinstein SM
AU  -  Fu W
AU  -  Hungria V
AU  -  Cengiz Seval G
AU  -  Farias JS
AU  -  Radocha J
AU  -  Maral S
AU  -  Turgut M
AU  -  Koh Y
AU  -  O'Leary D
AU  -  Schmidt Filho J
AU  -  Thertulien R
AU  -  An G
AU  -  Huang SY
AU  -  Grosicki S
AU  -  Tyczyńska A
AU  -  Banerjee R
AU  -  Pianko MJ
AU  -  Martínez-López J
AU  -  Steckiewicz P
AU  -  Maruyama D
AU  -  Fukushima K
AU  -  Oriol A
AU  -  Lopez Pardo J
AU  -  Goldschmidt H
AU  -  Pawlyn C
AU  -  Perrot A
AU  -  Zamagni E
AU  -  Dimopoulos MA
AU  -  Rasche L
AU  -  Tolbert J
AU  -  Terry W
AU  -  Courtoux C
AU  -  Liu X
AU  -  Vasey SY
AU  -  Connors K
AU  -  Festa M
AU  -  Heuck C
AU  -  Langlois A
AU  -  O'Rourke L
AU  -  Zhou J
AU  -  Qin X
AU  -  Lu J
AU  -  Gong J
AU  -  Vieyra D
AU  -  Voorhees PM
AU  -  MonumenTAL-3 Investigators.
PY  - 2026
JO  - N Engl J Med
DO  - 10.1056/nejmoa2604657
UR  - https://doi.org/10.1056/nejmoa2604657
ER  -

APA

R, M., M, B., P, R., W, C., MV, M., J, L., P, M., YC, C., CK, M., T, J., JC, Y., H, M., SM, R., W, F., V, H., G, C. S., JS, F., J, R., S, M., M, T., Y, K., D, O., J, S. F., R, T., G, A., SY, H., S, G., A, T., R, B., MJ, P., J, M., P, S., D, M., K, F., A, O., J, L. P., H, G., C, P., A, P., E, Z., MA, D., L, R., J, T., W, T., C, C., X, L., SY, V., K, C., M, F., C, H., A, L., L, O., J, Z., X, Q., J, L., J, G., D, V., PM, V., & Investigators., M. (2026). Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.. N Engl J Med. https://doi.org/10.1056/nejmoa2604657

Source records